A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

NCT05375838 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

550

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2
Influenza

Interventions

BIOLOGICAL: mRNA-1073
BIOLOGICAL: mRNA-1010
BIOLOGICAL: mRNA-1273
BIOLOGICAL: Placebo

Sponsor

ModernaTX, Inc.